gmp
gmp

Find Approved Drugs for Cardiology/Vascular Diseases in Clinical Development in JAPAN

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Edoxaban

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Du-176b

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 11, 2020

            Details:

            This application is based on results from the Japanese phase 3 clinical trial (ELDERCARE-AF Study) in 984 non-valvular atrial fibrillation patients of 80 years and above with a high bleeding risk and who are ineligible for other available anticoagulation therapies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Cheplapharm Arzneimittel Gmbh

            Deal Size: Undisclosed Upfront Cash: $562.0 million

            Deal Type: Divestment September 08, 2020

            Details:

            The portfolio to be divested to Cheplapharm is comprised Cardiovascular/Metabolic and Anti-Inflammatory products along with Calcium.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Edoxaban

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Du-176b

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 31, 2020

            Details:

            Primary endpoint has been achieved in the Japan phase 3 clinical trial (ELDERCARE AF Study; hereinafter, the study) for the anticoagulant, edoxaban, in elderly patients with non-valvular atrial fibrillation and high bleeding risk.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bempedoic Acid

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nilemdo

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 28, 2020

            Details:

            Daiichi Sankyo Europe GmbH announced that NILEMDO® (bempedoic acid) has demonstrated consistent tolerability and sustained efficacy over 2.5 years, in results presented at the ESC Congress 2020, the annual meeting of the European Society of Cardiology.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Metoprolol Tartrate

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lopressor

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: SIT Laboratorio Farmaceutico

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition August 03, 2020

            Details:

            LOPRESSOR® and ICAZ® are oral treatments of essential hypertension. LOPRESSOR® is a beta blocker indicated in treatment of hypertension. ICAZ® is a calcic inhibitor indicated in the treatment of essential hypertension.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Landiolol Hydrochloride

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Onoact

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 29, 2020

            Details:

            This approval is based on the result of a multi-center, randomized, open-label, parallel-group, late Phase Ⅱ / Ⅲ study (J-Land 3S study: ONO-1101-32) conducted in Japan, in patients with tachyarrhythmia associated with sepsis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Evolocumab

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Amgen Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition January 23, 2020

            Details:

            Under the acquisition, Amgen Astellas BioPharma will change its name to Amgen K.K., and simultaneously relocate its Headquarters to Tokyo Midtown.